v3.26.1
Condensed Consolidated Balance Sheets - USD ($)
Feb. 28, 2026
Dec. 31, 2025
May 31, 2025
Dec. 31, 2024
May 31, 2024
Current assets:          
Cash and cash equivalents   $ 3,452,891   $ 874,238  
Accounts receivable $ 107,400        
Other receivables and prepayments   139,633   85,316  
Total current assets   3,592,524   959,554  
Long-term investments, net   15,098,846   15,098,846  
Long-term deposits     71,823  
Total Assets   18,691,370   16,130,223  
Property and equipment, net      
Current liabilities:          
Convertible notes payable, current   3,418,500   3,238,500  
Accounts payable and accrued expenses   1,071,715   918,611  
Operating lease liabilities, current   24,428   102,225  
Total current liabilities   4,593,823   4,338,980  
Operating lease liabilities, non-current     14,182  
Total Liabilities   4,899,823   4,353,162  
Commitments and contingencies      
TEMPORARY EQUITY          
Contingently redeemable warrants   47,000    
Total temporary equity   47,000    
EQUITY          
Additional paid-in capital   97,000,188   93,474,825  
Accumulated other comprehensive (loss) income   (92,310)   89,162  
Accumulated deficit   (73,792,798)   (72,429,528)  
Total stockholders’ deficit   23,115,160   21,134,514  
Non-controlling interests   (9,370,613)   (9,357,453)  
Total equity   13,744,547   11,777,061  
Total Liabilities, Temporary Equity and Equity   18,691,370   16,130,223  
Related Party          
Current liabilities:          
Amounts due to related parties   79,180   79,644  
Convertible notes to a related party   3,418,500   3,238,500  
Convertible notes to a related party   306,000    
DiamiR Biosciences Corp          
Current assets:          
Cash and cash equivalents 235,736   $ 56,836   $ 70,276
Accounts receivable 107,400     89,281
Other receivables and prepayments 10,513   46,649   120,139
Total current assets 353,649   103,485   279,696
Total Assets 642,362   384,624   579,833
Property and equipment, net 12,343   20,029   40,857
Right of use asset, net 78,609   63,349   61,519
Intangible assets 197,761   197,761   197,761
Current liabilities:          
Convertible notes payable, current 1,282,717      
Accounts payable and accrued expenses 699,842   231,858   148,648
Operating lease liabilities, current 45,969   41,383   40,178
Deferred revenue 10,000   43,982  
Total current liabilities 2,038,528   317,223   188,826
Commitments and contingencies      
EQUITY          
Preferred stock value    
Ordinary shares, value 4,441   4,441   4,441
Additional paid-in capital 4,741,863   4,729,169   4,670,165
Accumulated deficit (6,172,413)   (5,822,571)   (5,079,336)
Total stockholders’ deficit (1,426,109)   (1,088,961)   (404,730)
Total equity (1,426,109)   (1,088,961)   (404,730)
Total Liabilities, Temporary Equity and Equity 642,362   384,624   579,833
DiamiR Biosciences Corp | Related Party          
Current liabilities:          
Operating lease liabilities, non-current 29,943   22,698   22,036
Convertible notes to a related party   957,662   614,182
Income taxes payable   176,002   159,519
Total Liabilities $ 2,068,471   $ 1,473,585   $ 984,563
Class A Ordinary Shares          
EQUITY          
Ordinary shares, value   62   37  
Class B Ordinary Shares          
EQUITY          
Ordinary shares, value   $ 18   $ 18